Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crescent Biopharma, a clinical-stage biotech focused on oncology therapies, announced the closing of an underwritten public offering of approximately 9.4 million ordinary shares and pre-funded warrants, raising gross proceeds of around $143.7 million. The offering included the full exercise of the underwriters' option to purchase additional shares.…